Hi-Tech Pharmacal Co. Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Hi-Tech Pharmacal Co. Inc.
Private Company Edition: In the latest round of $100m-plus venture capital financings, CG Oncology, MBX Biosciences and Jnana Therapeutics raised $120m, $115m and $107m, respectively. Also, MVM Partners closed a $500m fund and former Sage CEO leads incubator ABio-X in Massachusetts.
The clinical and cost-effectiveness of Paxlovid, RoActemra, Olumiant, Ronapreve, Lagevrio, Veklury, Xevudy and Evusheld are discussed in a draft guidance from England’s health technology assessment institute, which says it is ready to work with the companies whose products it has not recommended.
Disappointment & Surprise But Not Giving Up: Companies Respond To English Funding Rejection For COVID-19 Treatments
MSD, Gilead, GSK, AstraZeneca and Roche told the Pink Sheet what they thought of draft guidance that the health technology assessment institute, NICE, published today, recommending against routine commissioning for five COVID-19 treatments.
Industry experts at BioFuture 2022 highlighted the growing importance of digital technology in drug discovery and development, and also the limitations remaining.
- Other Names / Subsidiaries
- ECR Pharmaceuticals